AstraZeneca/Bristol's Onglyza Gains Approval, But Now Has To Face Januvia
Executive Summary
Gaining FDA approval was only the first hurdle for AstraZeneca and Bristol-Myers Squibb's dipeptidyl peptidase-4 inhibitor Onglyza. A potentially even bigger challenge now lies ahead: positioning the drug against Merck's first-in-class blockbuster Januvia
You may also be interested in...
Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?
Tradjenta's label supporting use in renally-impaired patients, with no need to adjust dose, could help differentiate the product's safety profile in a competitive space.
Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?
Tradjenta's label supporting use in renally-impaired patients, with no need to adjust dose, could help differentiate the product's safety profile in a competitive space.
Novo Disappoints With No Liraglutide News, But Growth Is Strong
Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.